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Abstract
Spinal Muscular Atrophy (SMA) is caused by diminished function of the Survival of Motor Neuron (SMN) protein, but the
molecular pathways critical for SMA pathology remain elusive. We have used genetic approaches in invertebrate models to
identify conserved SMN loss of function modifier genes. Drosophila melanogaster and Caenorhabditis elegans each have a
single gene encoding a protein orthologous to human SMN; diminished function of these invertebrate genes causes
lethality and neuromuscular defects. To find genes that modulate SMN function defects across species, two approaches
were used. First, a genome-wide RNAi screen for C. elegans SMN modifier genes was undertaken, yielding four genes.
Second, we tested the conservation of modifier gene function across species; genes identified in one invertebrate model
were tested for function in the other invertebrate model. Drosophila orthologs of two genes, which were identified
originally in C. elegans, modified Drosophila SMN loss of function defects. C. elegans orthologs of twelve genes, which were
originally identified in a previous Drosophila screen, modified C. elegans SMN loss of function defects. Bioinformatic analysis
of the conserved, cross-species, modifier genes suggests that conserved cellular pathways, specifically endocytosis and
mRNA regulation, act as critical genetic modifiers of SMN loss of function defects across species.
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Introduction
Decreased Survival of Motor Neuron (SMN) protein function
underlies most Spinal Muscular Atrophy (SMA) cases [1]. The
SMN protein is ubiquitously expressed [2,3], yet SMA pathology
is remarkably specific. Patients lose spinal a-motorneurons and
experience muscular dysfunction with atrophy. Mild cases result in
slowly progressing muscular weakness, while severe cases dramat-
ically perturb proximal neuromuscular function resulting in
childhood death [4]. There is no effective treatment for SMA
and at least 1 in 40 people in the US population are carriers of
SMN loss of function disease alleles [5–7].
The SMN protein is a component of the well-characterized
Gemin complex, which assembles splicing machinery in eukary-
otes [8–10]. SMN also associates with b-actin mRNA during
anterograde transport in neuronal processes suggesting a role for
SMN in mRNA transport, sub-cellular localization and/or local
translation [11–15]. In addition, SMN is found in post-synaptic
densities and Z-discs of muscles along with other RNA processing
proteins [11–19]. Roles for SMN in small nucleolar RNA
(snoRNA) and microRNA (miRNA) pathways have also been
suggested [20–22]. The relative contributions of SMN in these
various compartments and the relative importance of SMN
function in neurons and muscles for SMA pathology have been
difficult to determine. Various tissue requirements for SMN
function have been observed in different SMA model systems
[23–27]. The diverse subcellular SMN localization and varied
cellular requirements for SMN function suggest that this protein
may act in multiple cellular compartments including the
neuromuscular junction (NMJ) [28].
To determine in an unbiased fashion which cellular and
molecular pathways are particularly relevant to SMA pathology,
researchers have turned recently to genetic approaches in
vertebrates and invertebrates. The identification of SMN loss of
function modifier genes can reveal important biochemical
pathways for SMA pathology. Studies in patients have already
identified two genes that act as modifiers of SMA: SMN2 and
Plastin 3 (PLS3).
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The SMN1 gene encodes only full-length SMN protein while the
SMN2 gene encodes two different transcripts; 10% of SMN2
transcripts encode a full-length SMN protein identical to the
SMN1 gene product. However, due to a change in the splice
consensus sequence, 90% of SMN2 transcripts contain a stop
codon at the beginning of exon 7 and, therefore, encode a
truncated protein (called SMNdeltaEx7 or D7SMN) of diminished
function and stability [1,29–31]. Humans have various numbers of
SMN2 genes; patients with more copies of SMN2 generally have
later onset/less severe symptoms than patients with fewer copies of
SMN2. Decreased severity and delayed onset is usually attributed
to increased full-length SMN levels from SMN2 in vivo [17,32–36].
PLS3 may modulate the severity of SMA. In several families,
daughters who lack SMN1 and over-express PLS3 were remarkably
unaffected [37]. PLS3 encodes a conserved calcium-binding, actin-
bundling/stabilizing protein that is broadly expressed in various
tissues including blood, muscles and neurons [38–40]. Loss of the
yeast PLS3 ortholog, Sac6p, results in defective endocytosis [41,42].
Altering PLS3 levels modified SMN loss of function defects in
zebrafish motorneurons consistent with results in human families
and PLS3 co-precipitated with SMN from neuronal tissues [37].
However, increased PLS3 (due to profilin knockdown) did not
decrease the defectsinanSMAmousemodelanditremains unclear
how PLS3 might modify SMN neuromuscular defects [43].
Modifier genes identified in patient populations are clearly
pertinent to SMA pathology. However, studies in humans are
limited by kindred sizes and other considerations. As SMN
orthologs are found in C. elegans and Drosophila melanogaster, it may
be more efficient to identify SMA modifier genes in these powerful
invertebrate models. SMN loss of function models have already
been defined in C. elegans and Drosophila [18,25,44,45]. Loss of
Drosophila Smn (DmSmn) causes larval lethality and NMJ defects;
DmSmn function is required in neurons and muscles in flies [26].
Loss of C. elegans SMN-1 (Cesmn-1) also causes neuromuscular
function deficits followed by larval lethality [44]. Expression of
Cesmn-1 in neurons dramatically restores neuromuscular function,
whereas expression in muscles has little effect [44]. Given SMN
conservation across species, genes that act as SMN loss of function
modifiers in invertebrates could be important in SMA pathology
in humans (e.g. PLS3) [37].
In a recent study, twenty-seven P-element transposon insertion
lines were identified in Drosophila that modified SMN loss of function
defects, and a role for the TGF-beta pathway in SMN loss of
function pathologywas delineated [26]. However, itremains unclear
for several P-element lines which Drosophila gene near the transposon
insertion site is responsible for modulating SMN phenotypic defects.
The Drosophila P-element lines carried an inducible GAL4-UAS that
could drive either over-expression or antisense RNAi expression of
neighboring genes depending on transposon insertion site. Addi-
tionally,insertionoftheP-elementitselfmightperturb genefunction.
Eliminating ambiguity regarding modifier gene identity would
increase the utility of the Drosophila study.
To explore the genetic circuitry affecting SMN activity in C.
elegans, the Cesmn-1(lf) growth defect phenotype was used as a
metric in a rapid large-scale genetic screen. Growth may be
affected by a variety of changes, such as body length and longevity.
Subsequently, modifier genes were tested using a C. elegans
behavioral assay, the pharyngeal pumping, which is likely more
pertinent to SMN loss of function neuromuscular defects. In
addition, to identify conserved invertebrate SMN modifier genes,
we utilized previously described Drosophila assays to assess genetic
interaction of DmSmn with Drosophila orthologs of C. elegans modifier
genes. In the study by Chang and co-workers, the DmSmn lethal
phenotype correlated with NMJ defects for virtually all DmSmn
modifier genes, suggesting that lethality and neuromuscular
bouton number are effective measures of genetic interaction with
the Drosophila SMN ortholog [26].
Here, we define conserved genetic modifiers of SMN loss of
function using C. elegans and Drosophila. We find that PLS3
orthologs act as SMN modifier genes in both invertebrate species.
A genome-wide RNAi screen in C. elegans identified four new SMN
modifier genes, including ncbp-2 and flp-4, which also modify SMN
loss of function defects in Drosophila. Candidate SMN modifier
genes identified in a previous Drosophila screen were tested in C.
elegans yielding twelve cross-species modifier genes. Examination of
the literature for these genes suggested specific cellular pathways
that are critical genetic modifiers of SMN function: endocytosis
and RNA processing. These pathways may also be pertinent to
SMN loss of function defects in patients with SMA.
Results
The previously described Cesmn-1(ok355) deletion allele causes a
complete loss of Cesmn-1 function and is referred to herein as
Cesmn-1(lf) [44]. Cesmn-1(lf) is recessive; heterozygous animals are
overtly normal. To facilitate identification of heterozygous versus
homozygous animals, we utilized the balanced strain hT2(bli-
4(e937) let-?(q782) qIs48[myo-2p::GFP])/Cesmn-1(lf) (abbreviated +/
Cesmn-1(lf) [44,46]. Heterozygous +/Cesmn-1(lf) animals express
pharyngeal GFP, homozygous Cesmn-1(lf) progeny do not express
GFP, and progeny homozygous for the hT2 balancer die as GFP-
expressing embryos.
Although complete loss of SMN function causes lethality, C.
elegans that are homozygous mutant for Cesmn-1(lf) can survive for
several days due to partial maternal rescue. It has been suggested
that +/Cesmn-1(lf) hermaphrodites load sufficient Cesmn-1 maternal
protein and/or perhaps mRNA into oocytes to support develop-
ment through embryogenesis and early larval stages [44].
Accordingly, homozygous Cesmn-1(lf) larvae initially resemble wild
type animals. Eventually maternally-loaded Cesmn-1 product is lost;
Cesmn-1(lf) animals grow more slowly than +/Cesmn-1(lf) siblings,
Author Summary
Spinal Muscular Atrophy (SMA) is a common, untreatable,
and often fatal neuromuscular disease predominately
caused by reduced Survival Motor Neuron (SMN) protein
function. Here, we use invertebrate models to identify and
validate conserved genes that play a critical role in SMN
loss of function neuromuscular defects. Decreased SMN
function causes growth defects in the nematode Caenor-
habditis elegans and in the fruit fly Drosophila melanoga-
ster—as well as behavioral or synaptic connectivity defects
between neurons and muscles, respectively. We found that
a genetic modifier of SMA in patients, plastin, also affects
SMN function in these invertebrate models. We undertook
a genome-wide RNAi screen to identify genes whose
perturbation alters the growth defects of C. elegans lacking
SMN. These genes were validated in neuromuscular assays
in nematode and fly models of SMA. Additionally, we
used the C. elegans model to test SMN modifier genes
previously identified in the Drosophila SMA model.
Combined, these cross-species approaches identified
fifteen genes that are important in both species when
SMN function is decreased. Related mammalian proteins
and the pathways in which they act (including endocytosis
and RNA transport/translational control) are likely impor-
tant players in SMA.
Invertebrate Modifiers of SMN
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adulthood (Figure 1A). Combined, these defects decrease the
average size of the Cesmn-1(lf) population versus control animals;
decreased average population size will be referred to herein as a
growth defect. This growth defect was harnessed in an automated
assay toidentify Cesmn-1(lf) modifier genesina genome-wide screen.
C. elegans growth assay
To validate growth as an assay for SMN modifier gene
identification, we first demonstrated that RNAi knockdown of
Cesmn-1 or the invertebrate ortholog of Plastin 3 (PLS3) altered
Cesmn-1(lf) growth. The C. elegans gene plst-1 (PLaSTin (actin bundling
protein) homolog-1) encodes a predicted protein similar to PLS3.
To knockdown gene function, C. elegans were reared on bacteria
producing double stranded RNA corresponding to the gene of
interest, a strategy known as ‘feeding RNAi’ [47]. Feeding RNAi
decreases gene transcripts in most C. elegans tissues although
knockdown in neurons is generally less effective than knockdown
in muscles, germline, and other tissues [48–50]. Here, animals
were reared for two generations on solid media and RNAi feeding
bacteria corresponding to Cesmn-1 or plst-1, allowing knockdown of
maternal and zygotic transcripts (Figure 1B). Bacteria containing
the empty RNAi feeding vector were used as a negative control
(empty(RNAi)).
An automated system was used to simultaneously measure
growth and determine genotype for the progeny of +/Cesmn-1(lf)
animals (Figure 1C). The COPAS BioSorter (Union Biometrica,
Holliston, MA) measures C. elegans length as ‘time-of-flight’, which
is the time required for the animal to pass through the
fluorescence-detection chamber [51]. Cesmn-1(lf) homozygous
animals do not express GFP while +/Cesmn-1(lf) heterozygous
animals express GFP and are longer than Cesmn-1 homozygous
animals of the same late larval or adult stage. Animals smaller than
the L2 larval stage were excluded from this analysis to avoid
bacterial debris. The percentage of large adult animals was
determined for each genotype and RNAi treatment.
RNAi knockdown of Cesmn-1 decreased the percentage of large
animals in both Cesmn-1(lf) homozygous and +/Cesmn-1(lf)
heterozygous populations (Table 1, Rows 1 & 2). Initially, it
seems counter-intuitive that the defects of Cesmn-1(lf) animals are
exacerbated by Cesmn-1(RNAi). However, in this scenario,
transcripts in both the somatic tissues and germline of +/Cesmn-
1(lf) heterozygous animals are targeted and, consequently,
maternally-loaded Cesmn-1 transcript and protein are depleted in
homozygous Cesmn-1(lf) progeny, abrogating partially the observed
maternal rescue. The ability of Cesmn-1(RNAi) to exacerbate
Cesmn-1(lf) defects suggests that the effects of modifier genes can be
assessed using RNAi feeding.
Knockdown of the C. elegans PLS3 ortholog, plst-1, increased the
average length of the +/Cesmn-1(lf) population, but did not
significantly alter the average length of Cesmn-1(lf) animals
(Table 1, Rows 1 & 3). Genetic interaction with plst-1 was further
confirmed by using the plst-1 (tm4255) mutant allele (Table 2). The
average length of +/Cesmn-1(lf);plst-1(tm4255) adult animals was
significantly increased in relation to +/Cesmn-1(lf) animals. In
contrast, the average length of homozygous Cesmn-1(lf);plst-
1(tm4255) was not altered, recapitulating the results of plst-
1(RNAi). Increased average adult length is an overall growth
metric thzat may encompass a variety of changes; decreased plst-1
function, by RNAi or mutant allele, could increase length, cause
sterility, and/or increase longevity in +/Cesmn-1(lf) control
animals. It appears that loss of Cesmn-1 function suppresses the
effects of decreased plst-1 function (i.e. increased length was not
observed in Cesmn-1(lf);plst-1(tm4255) homozygous mutant ani-
mals). The genetic and functional relationship between SMN and
PLS3 bears further examination; as plst-1 and Cesmn-1 have
opposing effects on the growth assay and since Cesmn-1(lf);plst-
1(tm4255) animals resemble Cesmn-1(lf) single mutants, Cesmn-1
may act downstream of plst-1 in this growth assay [52].
Growth modifier genes identified in C. elegans
genome-wide screen
To identify additional genes that modify SMN loss of function
defects, a large-scale genome-wide screen for enhancers and
suppressors of the Cesmn-1(lf) growth defect was undertaken. The
growth assay was adapted to a higher-throughput 96-well, liquid
Figure 1. Survival and average length of Cesmn-1(lf) animals is decreased. Homozygous loss of Cesmn-1(lf) results in slower growth and
most animals die during larval stages. Animals that reach the adult stage are short-lived and sterile. A) Image of age-matched heterozygous
hT2(lethal)[myo-2p::GFP]/Cesmn-1(lf) (+/Cesmn-1(lf), described in text) and homozygous Cesmn-1(lf) individuals (below). Scale bar indicates 150
microns. B) To test the impact of candidate modifier genes on growth rates and size, a C. elegans growth assay was established. +/Cesmn-1(lf) animals
were collected as unhatched eggs, reared for 5 days/2 generations on standard C. elegans plates upon RNAi bacterial strains, as illustrated in the flow
chart. Bacterial cultures expressed dsRNA corresponding to the gene of interest for RNAi knockdown; bacterial cultures containing vector with no
insert were used as a control (‘empty’). C) Using an automated system, the length and fluorescence of animals was determined [51]; the smallest
larvae in each culture were indistinguishable from debris and were excluded from the analysis as illustrated in the graph. Genotypes were
discriminated by GFP fluorescence and length was determined as ‘time-of-flight’ through the laser chamber; each dot in the graph represents an
individual animal. The disparate growth/survival rates of Cesmn-1(lf) and +/Cesmn-1(lf) animals alters the percentage of ‘large’ animals in these mixed
stage cultures. As illustrated graphically, +/Cesmn-1(lf) and Cesmn-1(lf) animals can be sorted into blue and red boxes, respectively; animals
designated as ‘large’ fall into shaded boxes. The fraction of large animals was calculated (# animals in shaded box/# animals in both shaded and
unshaded box for each genotype) and is reported as % large with standard error of the mean (S.E.M.); significance was determined by Mann-Whitney
U two-tailed test with p#0.05. At least three independent cultures of more than 200 animals were scored for each targeted gene.
doi:10.1371/journal.pgen.1001172.g001
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RNAi feeding library was used for gene knockdown (Figure 2A)
[53]. Progeny of +/Cesmn-1(lf) animals were reared for two weeks
(more than 2 generations) on RNAi feeding bacterial strains before
assessment of growth using the COPAS Biosorter [51]. To identify
RNAi clones that specifically altered the growth of Cesmn-1(lf)
animals, a growth ratio of large to small animals was determined
for each clone for Cesmn-1(lf) and for +/Cesmn-1(lf) genotypes. If
the RNAi clone growth ratio was more than 2 standard deviations
away from the mean for Cesmn-1(lf) animals and within 0.7
standard deviations of the mean for +/Cesmn-1(lf) animals in at
least 40% of independent trials, then the corresponding gene was
designated as an Cesmn-1(lf) modifier (Figure 2B). In the primary
high-throughput screen, no suppressors were found, but four genes
were identified as enhancers (Figure 2B). RNAi knockdown of
these genes exacerbated homozygous Cesmn-1(lf) growth defects
and did not significantly alter the growth of heterozygous +/Cesmn-
1(lf) animals: ncbp-2, T02G5.3, grk-2, and flp-4. ncbp-2 encodes the
C. elegans Cap Binding Protein 20 (CBP20 or Cbp20) ortholog
[54]. T02G5.3 encodes a predicted protein of unknown function
with no vertebrate orthologs based on BLAST analysis. grk-2
encodes one of two G-protein coupled receptor kinases. flp-4
encodes an FMRFamide family neuropeptide protein. The low
number of modifiers identified in this screen versus the previous
Drosophila screen may reflect the stringent criterion utilized here or
the inefficiency of RNAi by feeding in neurons.
To determine if decreased adult body length accounts for the
enhanced Cesmn-1(lf) growth defect upon knockdown of ncbp-2,
T02G5.3, grk-2 and flp-4, the average body length of Cesmn-1(lf)
young animals was determined (Text S1 and Table S4, top panel).
Only ncbp-2(RNAi) significantly reduced the average body length of
Cesmn-1(lf) animals suggesting that the enhanced growth defect
caused by ncbp-2(RNAi) could be attributed to the Cesmn-1(lf)
shorter body size. The other three enhancer genes may alter
survival or growth as adult animals.
SMA is a neuromuscular disease and, therefore, our objective was
the identification of modifier genes that impact SMN neuromuscular
function. We then examined the impact of Cesmn-1 growth modifier
genes on Cesmn-1 loss of function neuromuscular defects using RNAi
and, when available, loss of function alleles of modifier genes.
RNAi knockdown of ncbp-2, grk-2, and T02G5.3 modified
Cesmn-1(lf) neuromuscular defects
A recentstudyfrom the Sattellelaboratorydemonstrated that loss
of Cesmn-1 function causes progressive defects in C. elegans
neuromuscular function in pharyngeal pumping [44]. C. elegans
feeds on bacteria and other microorganisms using a small, discrete
subset of neurons and muscles contained in the pharynx (Figure 3A)
[55]. Pharyngeal cell specification, neuronal development, and
myoblast fusion is completed within hours of hatching [56,57]. The
pharynx pumps continuously and symmetrically at over 250 beats
per minute in wild type animals when food is present and larval
pumping is interrupted only by molting under standard culture
conditions. We confirmed a previous report [44] that in early larval
stages, the pumping rates of Cesmn-1(lf) animals are indistinguish-
able from control animals, but at later larval stages Cesmn-1(lf)
pumpingratesdrop (Figure 3B).Cesmn-1(lf)animals haveprogressive
defects in pharyngeal pumping, which occur earlier than reported
locomotion defects.Atday2,62%ofCesmn-1(lf)animalsaremoving
spontaneously, but pumping rates have dropped dramatically
(Figure 3B). Restoration of Cesmn-1 function in neurons almost
completely restores pumping rates suggesting that Cesmn-1 is
required in neurons for this behavior [44].
The efficacy of RNAi by feeding in this neuromuscular assay
was assessed for Cesmn-1 and plst-1 using Cesmn-1(lf) and +/Cesmn-
1(lf) animals. Animals were allowed to hatch on RNAi feeding
plates and pumping rates were determined after three days. Either
plst-1(RNAi) or Cesmn-1(RNAi) decreased Cesmn-1(lf) pumping
rates, but not +/Cesmn-1(lf) pumping rates (Figure 3C). In
addition, plst-1(lf) significantly decreased the pumping rates of
Table 1. Conserved genes modify Cesmn-1(lf) defects in the
growth assay.
Ce gene Dm gene Cesmn-1(lf) +/Cesmn-1(lf)
% large ± SEM % large ± SEM
none none 18624 6 61
Cesmn-1 Smn 664* 3161*
plst-1 Fimbrin 15635 5 63*
uso-1 p115 764* 4461
nhr-85 Eip75B 865* 4461
egl-15 Breathless 965* 4561
atf-6 Atf6 1167* 4064
ape-1 CG18375 1169* 5062
kcnl-2 SK 1261* 4261
nekl-3 Nek2 1363* 4362
atn-1 Actinin 2364* 4361
cash-1 CG33172 26656 4 611*
dlc-1 cut up 15686 6 63*
C. elegans modifier genes are listed in column 1 and orthologous Drosophila
genes are listed in column 2. Only genes that significantly altered the
percentage of large Cesmn-1(lf) homozygous animals (column 3) or +/Cesmn-
1(lf) heterozygous animals (column 4) are presented. Animals were reared for
two generations on bacterial RNAi strains targeting the C. elegans gene prior to
growth analysis as described in Figure 1. The percentage of large animals was
determined for each genotype after RNAi knockdown of the indicated C.
elegans gene and is reported with standard error of the mean (S.E.M.). Large
animals include adults, L4 and L3 stage larvae. This assay does not distinguish
between slow growth, changes in relative length, and altered viability. Three to
six independent determinations were undertaken for each genotype/RNAi
culture and the percentage of large animals in each trial was averaged.
Significant changes from empty(RNAi) for each RNAi/genotype using the two-
tailed Mann-Whitney U test (p,0.05) are indicated with an asterisk. See Table
S1 for results for all genes tested and Materials and Methods for details.
doi:10.1371/journal.pgen.1001172.t001
Table 2. C. elegans orthologs of PLS3, GRK, and FMRFamide
modify Cesmn-1(lf) growth defects.
Ce genotype Ce gene Cesmn-1(lf) +/Cesmn-1(lf))
RNAi target %l a r g e± SEM % large ± SEM
none 27624 4 62
plst-1(tm4255) none 39656 7 62*
grk-2(rt97) none 1061* 4161
flp-4(yn35) none 20625 1 62
The growth defects of +/Cesmn-1(lf) and Cesmn-1(lf) animals were examined in
the presence of grk-2(rt97), flp-4(yn35) and plst-1(tm4255) loss of function alleles;
alleles for each modifer gene are listed in column 1. The percentage of large
animals was determined for Cesmn-1(lf) homozygous animals (column 3) or
+/Cesmn-1(lf) heterozygous animals (column 4). At least three independent
determinations were undertaken for each genotype. Significance versus control
genotypes (+/Cesmn-1(lf) and Cesmn-1(lf)) was determined using Chi-square
analysis (p,0.05 indicated with an asterisk). S.E.M. is also reported.
doi:10.1371/journal.pgen.1001172.t002
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Cesmn-1 in the neuromuscular pharyngeal pumping assay
(Figure 3D). This exacerbation of Cesmn-1 loss of function defects
by plst-1 manipulation is consistent with results in other organisms
[37]. The ability of Cesmn-1(RNAi) and plst-1(RNAi) to alter
pumping of homozygous mutant Cesmn-1(lf) animals suggests that
candidate modifier genes can be assessed using RNAi knockdown
in this neuromuscular assay.
The four modifier genes from the C. elegans growth screen were
tested for function as Cesmn-1 neuromuscular modifier genes using the
pharyngeal pumping assay. Results are summarized in Figure 4A.
ncbp-2(RNAi) and T02G5.3(RNAi) enhanced and suppressed the
pharyngeal pumping defects of Cesmn-1(lf) animals, respectively; flp-
4(RNAi) and grk-2(RNAi) had no significant effect compared to
controls. We suggest that ncbp-2 and T02G5.3 are likely modifiers of
Cesmn-1(lf) neuromuscular defects based on RNAi results.
Loss of grk-2 enhances Cesmn-1(lf) growth and
neuromuscular defects
RNAi knockdown of C. elegans genes by feeding is robust in
virtually all cell types but can often be inefficient and can result in
only partial loss of gene function, especially in the nervous system
[58,59]. To address the specificity of the genetic modifiers, the
RNAi results were confirmed by using mutant alleles when
possible; alleles of ncbp-2 and T02G5.3 were not available.
A grk-2 loss of function allele has been previously described, grk-
2(rt97) [60]. Loss of grk-2 significantly enhanced the growth defects
of Cesmn-1(lf) animals (Table 2). Additionally, the pumping rates of
grk-2(lf) animals derived from hT2 parents were not significantly
lower than those of control animals, but the average pumping rates
of Cesmn-1(lf) grk-2(lf) double mutant animals were significantly
lower than the pumping rates of either single mutant (Figure 4B).
This suggests that grk-2 loss enhances both Cesmn-1(lf) growth and
pharyngeal pumping defects. A grk-2 gain of function allele is not
available and transgenes are unstable in +/Cesmn-1(lf) animals
(unpublished results and [44]).
To test the genetic interaction of flp-4 with Cesmn-1,w e
identified a flp-4 loss of function allele, flp-4(yn35), using PCR
based screening techniques [61–65]. The flp-4(yn35) deletion
removes all sequences encoding FLP-4 FMRFamide neuropep-
tides and likely causes a complete loss of flp-4 function ([66] and C.
Li, in preparation). Although flp-4(yn35) reduced the percentage of
Cesmn-1(lf) large animals in the growth assay, the difference was
not statistical significant different (Table 2). Similar results were
obtained using the pharyngeal pumping assay. The pumping rates
of flp-4(lf) animals were slightly lower, but not significantly
different than control animals. Loss of flp-4 function decreased
pumping rates of Cesmn-1(lf) animals in five independent trials, but
the difference was not statistically significant (p=0.236, Figure 4B).
Either flp-4 is not a bona fide modifier or flp-4(RNAi) may act off-
target decreasing the function of more than one of the 32 other C.
elegans FMRFamide genes [67].
Drosophila orthologs of plst-1, ncbp-2 and flp-4 modify
SMN neuromuscular defects
SMN modifier genes that are conserved across species would be
of considerable interest. Three of the candidate genes identified in
the C. elegans screen encode conserved proteins with clear orthologs
in other species: grk-2, flp-4, and ncbp-2. To determine if their
orthologs modify SMN loss of function defects, we turned to the
fruit fly Drosophila. Decreased function in the Drosophila SMN
ortholog Smn (DmSmn) results in growth defects, early pupal
arrest, and NMJ synaptic defects [26]. We utilized pre-existing
Drosophila loss of function alleles and previously described Drosophila
assays to assess genetic interaction of DmSmn with Drosophila
orthologs of C. elegans modifier genes [18,25,26].
First, we determined if Fimbrin (Fim), the Drosophila ortholog of
PLS3, modifies DmSmn loss of function defects in growth and
NMJ assays. It has been shown that RNAi knockdown of DmSmn
(DmSmn RNAi) results in 44% lethality in early pupal stages with
56% lethality at late pupal stages [26]. Loss of Fim alone does not
cause larval or pupal lethality (data not shown). Three Fim loss of
Figure 2. Genome-wide RNAi screen for Cesmn-1(lf) modifier genes. A) To identify genes whose knockdown modifies the growth of Cesmn-
1(lf) animals, the progeny of hT2(lethal)[myo-2p::GFP]/Cesmn-1(lf) (+/Cesmn-1(lf), described in text) were reared for more than 2 generations in 96-well,
liquid culture format on bacteria expressing dsRNA corresponding to over 16,500 C. elegans genes. Modifier genes identified in this assay were tested
subsequently in neuromuscular assays in C. elegans and Drosophila.B )Cesmn-1(lf) and +/Cesmn-1(lf) length was measured for each RNAi clone and a
‘growth’ ratio of large:small animals was determined for each genotype. Representative graphs illustrate the distribution of RNAi clone growth ratios.
Candidate enhancer genes were those with a growth ratio more than 2 standard deviations above the mean for Cesmn-1(lf) (shaded in right graph)
and within 0.7 standard deviations of the mean for +/Cesmn-1(lf) (shaded in left graph) for each 96-well plate. No suppressors were identified using
similar criteria. Two independent determinations were made for each clone in the original screen. Candidate genes were retested in at least
quadruplicate and enhanced growth in at least 40% of trials before designation as growth modifier genes; average growth ratios of enhancers from
the C. elegans screen are indicated.
doi:10.1371/journal.pgen.1001172.g002
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and each accelerated death compared to DmSmn(RNAi) control
animals (Figure 5A).
In Drosophila, loss of SMN function results in a dose-dependant
decrease in process arborization at the NMJ and diminished numbers
of synaptic specializations, termed synaptic boutons [26]. Boutons are
visualized as coincident pre-synaptic synaptotagmin and post-
synaptic Discs large protein immunoreactivity. The number of
synaptic boutons found between Drosophila neurons and muscles
provides a simple and readily quantifiable assessment of phenotypic
severity. We determined if the Drosophila PLS3 ortholog Fim might
also modify the NMJ defects of DmSmn. RNAi knockdown of
DmSmn using the ubiquitous tubulin promoter (TubGAL4;SmnR-
NAi) modestly decreased synaptic innervation in Drosophila larvae
(reported as bouton numbers per muscle area, Figure 5B). Loss of
Drosophila Fim function in Fim
d02114 animals also modestly decreased
bouton density. We found that effects of Fim
d02114 and DmSmn
knockdown were synergistic; bouton numbers were significantly
decreased suggesting that loss of Fim function exacerbated DmSmn
loss of function defects, being consistent with studies in vertebrate
models of SMA [37]. These results suggest that PLS3 is a cross-
species modifier of SMN function.
Next, Drosophila orthologs of candidate SMN modifier genes
from C. elegans were examined. Cbp20 and Fmrf were selected as
Drosophila orthologs of ncbp-2 and flp-4, respectively, based on
similarity and Drosophila loss of function alleles were obtained.
(There are 32 genes in C. elegans encoding 32 FMRFamide-related
neuropeptides, in contrast, three FMRFamide genes exist in
Drosophila. There may be less redundancy in FMRFamide gene
function in Drosophila [68,69,70]).
Heterozygous loss of DmSmn function in +/Smn
73Ao or
+/Smn
f01109 animals had no significant effect on bouton number
as expected, Smn
73Ao/Smn
f01109 animals had dramatically
decreased bouton numbers (Figure 6). Loss of one copy of
Cbc20 or Fmrf modestly decreased synaptic bouton number
compared to control animals. However, simultaneous loss of one
Figure 3. Loss of C. elegans PLS3 ortholog enhances the pharyngeal pumping defects of Cesmn-1(lf) animals. During feeding the C.
elegans pharynx contracts at over 200 times per minute to capture and grind bacteria. A) Pharyngeal pumping rates can be determined by
videotaping feeding and counting contractions as movement of the grinder (indicated by arrow) at slower playback speeds; scale bar indicates 40
microns. B) The progeny of hT2(lethal)[myo-2p::GFP]/Cesmn-1(lf) (+/Cesmn-1(lf)) animals were allowed to hatch on bacterial strains on standard C.
elegans plates. Pumping rates of +/Cesmn-1(lf) heterozygous and Cesmn-1(lf) homozygous animals were determined on different days (day 1–4) on a
control ‘empty vector’ bacterial strain. Decreased locomotion (sinusoidal movement) was also scored as uncoordinated (Unc). At day 1, the pumping
rates and locomotion of Cesmn-1(lf) animals are identical to +/Cesmn-1(lf) or wild type animals. By day 2, the average pumping rates dropped
dramatically (as previously reported [44]) and roughly 20% of animals were uncoordinated (column on right). By day 3 and 4, the pumping rates and
locomotion of the majority of surviving animals are defective. Expressing Cesmn-1 in neurons is sufficient to restore pumping rates to near normal
levels [44]. The behavior of Cesmn-1(lf) animals is initially normal due to maternal loading of Cesmn-1 gene products, but as the maternal contribution
is depleted, loss of Cesmn-1 causes progressive defects in neuromuscular function. C) Pumping rates of +/Cesmn-1(lf) and Cesmn-1(lf) animals were
determined at 3 days post-hatching on bacterial feeding strains expressing dsRNA corresponding to Cesmn-1 and plst-1 genes; ‘empty vector’
bacterial cultures were used as a control (‘empty’). plst-1(RNAi)o rCesmn-1(RNAi) significantly descreased Cesmn-1(lf) pumping rates, but not +/Cesmn-
1(lf) pharyngeal pumps. D) Decreasing plst-1 function has no effect on pumping rates in heterozygous +/Cesmn-1(lf) animals, but pumping rates were
significantly decreased in Cesmn-1(lf); plst-1(tm4255) double mutant animals. At least 20 animals were scored for each genotype in at least 2
independent trials. Pumping rates reported are the average of all animals in all trials. Because of the known impact of chromosomal pairing on
histone methylation and gene expression [96], all animals tested herein were the progeny of animals carrying the hT2 balancer chromosome that
prevents recombination. S.E.M. is reported. Significance of p#0.05 is indicated with an asterisk and was determined using either an unpaired two-
sample t-test or a Mann-Whitney U two-tailed test according to sample-specific parameters [100].
doi:10.1371/journal.pgen.1001172.g003
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further synaptic bouton loss (Figure 6). The genetic interaction in
trans-heterozygous animals is consistent with a strong genetic
interaction between Smn and the two modifier genes. We were
unable to obtain classical alleles of the grk-2 Drosophila ortholog. We
conclude that Cbp20 and FMRFamide are conserved invertebrate
enhancers of Smn loss of function defects and that this genetic
interaction is conserved across species.
Testing Drosophila modifier genes in C. elegans assays
A previous Drosophila screen identified twenty-seven P-element
insertion lines that altered Drosophila SMN (DmSmn) loss of function
defects [26]. Cross-species validation of these genes might also help
elucidate conserved pathways that are critical in SMN loss of
function pathology. However, several genes flanked the P-element
insertion site for many of these modifier lines and the precise DmSmn
modifier gene could not be unambiguously identified. Therefore, 40
candidate modifier genes were reported [26]. We identified the
likely C. elegans orthologs for 32 of these 40 genes using reciprocal
BLAST similarity searching (Table S1). The ability of these genes to
modifyCesmn-1(lf)growthdefectswas assessedbyfeedingCesmn-1(lf)
and +/Cesmn-1(lf) animals bacteria expressing the corresponding
dsRNA;RNAifeedingcloneswereconstructedforB0432.13,dhs-22
and ugt-49 [53]. Twelve genes crossed species and modified Cesmn-
1(lf) defects in one or both C. elegans assays.
Orthologs of ten Drosophila genes modified Cesmn-1(lf)
growth defects
Knockdown of seven C. elegans genes (uso-1, nhr-85, egl-15, atf-6,
ape-1, kcnl-2 and nekl-3) orthologous to DmSmn modifier genes
specifically enhanced Cesmn-1(lf) growth defects, but did not
significantly alter the percentage of large heterozygous +/Cesmn-
1(lf)animals.KnockdownoftheC.elegansorthologatn-1significantly
suppressed thegrowthdefects ofCesmn-1(lf)animalswithoutaltering
the percentage of large +/Cesmn-1(lf) siblings. Finally, C. elegans
orthologs of two Drosophila genes were identified, whose genetic
interaction with Cesmn-1 resembled the interaction of plst-1 with
Cesmn-1: cash-1 and dlc-1. RNAi knockdown of these two genes
increased the percentage of large animals in the +/Cesmn-1(lf)
population without altering the Cesmn-1(lf) population. Growth
assay results for these ten genes are found in Table 1 (Rows 4
through13),resultsforall orthologstestedcanbe found inTableS1,
and a discussion of modifier gene function is presented in Text S2.
For bona fide cross-species modifier genes, the impact of modifier
genes on SMN loss of function defects should be conserved across
species (i.e. enhancer genes should enhance in both species). For six
cross-species genes, the impact of modifier gene loss on DmSmn
and Cesmn-1 loss of function defects was conserved as expected.
Specifically, the enhancement of Cesmn-1(lf) defects by RNAi
knockdown of nhr-85, egl-15, and kcnl-2 was consistent with the
effects of the corresponding Drosophila modifier genes on DmSmn
[26]; the corresponding Drosophila insertion lines (d09801, f02864,
and d03336) enhanced DmSmn defects and the transposon
insertion in these lines are predicted to decrease function. The
results for Drosophila orthologs of C. elegans uso-1 and nekl-3 were
also consistent across species. The exacerbation of Cesmn-1(lf)
growth defects observed after uso-1(RNAi) or nekl-3(RNAi) knock-
down was consistent with the suppression of DmSmn defects
observed after over-expression of the cognate Drosophila genes.
There was also good concordance for the effect of actinin
orthologs across invertebrate species. The d00712 Drosophila
insertion line likely drives over-expression of the Drosophila gene
Actinin (Actn) and enhances DmSmn defects [26,71,72], while
Figure 4. C. elegans RNAi screen identifies conserved SMN modifier genes. A) Four genes were identified as modifiers of Cesmn-1(lf) growth
defects in the C. elegans RNAi screen: ncbp-2, T02G5.3, grk-2 and flp-4. The pharyngeal pumping rates of homozygous mutant Cesmn-1(lf) and
heterozygous control +/Cesmn-1(lf) animals were determined at day 3 as described in Figure 3. B) For two C. elegans candidate modifier genes, flp-4
and grk-2, loss of function alleles were available. grk-2(rt97) significantly decreased the pumping rates of Cesmn-1(lf) animals, while flp-4(yn35)
lowered Cesmn-1(lf) pumping rates, but did not reach statistical significance (p=0.012 and p=0.236 by two-tailed Mann-Whitney U test, respectively).
Pumping rates were determined on day 3 post-hatching; at least 25 animals were scored for each genotype in at least 3 independent trials. Pumping
rates reported are the average of all animals in all trials. Significance versus Cesmn-1(lf) is indicated with an asterisk. To control for genetic
background, all animals tested were the progeny of animals carrying the balancer chromosome hT2[myo-2p::GFP]; control animals are hT2/Cesmn-1(lf)
siblings.
doi:10.1371/journal.pgen.1001172.g004
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C. elegans atn-1 was observed here.
For four genes, it is unclear if the results for Drosophila orthologs
are concordant across species: atf-6, ape-1, dlc-1 and cash-1. For atf-
6 and ape-1, the corresponding Drosophila transposons (d05057 and
d05779) are inserted into the 1
st intron of one of the two
transcripts predicted for the orthologous Drosophila genes; accord-
ingly, these transposons may perturb gene function or may drive
over-expression of the predicted 2
nd shorter transcript. For the
genes with complex genetic interactions with Cesmn-1 (i.e. dlc-1 and
cash-1), the function of Drosophila orthologs ctp and CKA are likely
decreased by Drosophila insertion lines f02345 and f04448, which
suppressed and enhanced DmSmn defects, respectively [26].
Overall, six of ten genes that modified DmSmn growth defects
are clearly concordant with the C. elegans growth data, suggesting
conserved roles as SMN loss of function modifiers.
Orthologs of three Drosophila genes modified Cesmn-1(lf)
neuromuscular defects
C. elegans orthologs of DmSmn modifier genes identified in the
previous Drosophila screen [26] were also rescreened using the
pharyngeal pumping assay. We found that RNAi knockdown daf-4
enhanced Cesmn-1(lf) pharyngeal pumping defects, while knock-
down of kncl-2 or nhr-25 suppressed Cesmn-1(lf) pumping defects
(Table 3, rows 3 through 5).
daf-4 encodes one of the C. elegans TGF-beta receptor subunits
orthologous to Drosophila Wit (Witless). In C. elegans, daf-4 and
TGF-beta/Dpp pathway function is required for cell specification
at numerous stages and for transit through the stress-resistant,
long-lived dauer stage [73]. RNAi knockdown of daf-4 exacerbated
Cesmn-1(lf) pumping defects, consistent with the effect of TGF-beta
pathway manipulation in Drosophila [26].
RNAi knockdown of two C. elegans genes diminished Cesmn-1(lf)
pumping defects: kcnl-2 and nhr-25. kcnl-2 encodes a likely C. elegans
SK channel subunit and nhr-25 is one of the two C. elegans proteins
most similar to Drosophila Usp (Ultraspiracle). No clear ortholog of
Usp is found in the C. elegans genome. The corresponding
Drosophila d00712 transposon insertion line likely drives over-
expression of Usp resulting in enhancement of DmSmn defects [26].
This is consistent with C. elegans results. By contrast, the impact of
SK/kcnl-2 loss in growth versus pumping assays is discordant. The
d03336 transposon insertion is located in the SK gene, likely
Figure 5. Loss of PLS3 orthologs enhances SMN loss of function defects in invertebrates. Previous studies in vertebrates suggested that
PLS3 orthologs in C. elegans and Drosophila might modify SMN loss of function defects [37]. A) A genetic interaction was found between the
Drosophila PLS3 ortholog (Fimbrin or Fim) and DmSmn using previously described DmSmn RNAi knockdown lines [26] and Fim loss of function
alleles. Percentage early or late larval lethality is reported. Ubiquitous RNAi knockdown of DmSmn using the tubulinGAL4 (TubGAL4) driver results in
pupal death; modifier genes alter the percentage of animals that die at early versus late pupal stages (day 7 versus day 9 [26]). Loss of Fim function
significantly increased the percentage of animals that died as early pupae (p#0.05 by Chi-square analysis); Fim is an enhancer of DmSmn loss of
function growth/survival defects. At least 100 animals of each genotype were scored in four replicates for the lethality assay. No significant variation
was observed between control and experimental crosses with each independent trial. B) The Drosophila d02114 allele likely eliminates Fim function
and in homozygous animals modestly perturbs NMJ morphology at larval muscle 4. Fim
d02114 enhances DmSmn loss of function NMJ defects
consistent with studies in vertebrates [37]. All strains carry the ubiquitous TubGAL4 driver. Significance of p#0.05 versus single mutant strains was
determined by ANOVA and is indicated with asterisk; S.E.M. is shown. In representative images, red corresponds to anti-Discs Large (DLG), green is
anti-synaptotagmin and blue is DAPI; scale bar indicates 15 microns.
doi:10.1371/journal.pgen.1001172.g005
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NMJ defects [26]. This is consistent with kcnl-2(RNAi) enhance-
ment of C. elegans growth defects described above. The suppression
of Cesmn-1(lf) pumping defects observed here after kcnl-2
knockdown may reflect differences in the requirement for kcnl-2
function in neuromuscular tissue and/or the relative inefficiency of
RNAi knockdown in neurons.
Modifier gene interactions implicate specific pathways
critical in neurodegenerative disease
To address the specificity of the invertebrate SMN modifier
genes, the impact of their RNAi knockdown was examined on an
unrelated pharyngeal pumping defective strain. Loss of egl-30
(ad805), which perturbs Gqa function in C. elegans, decreases their
pharyngeal pumping rates [74]. RNAi knockdown did not
significantly alter egl-30 pharyngeal pumping rates for any modifier
gene (Table S3), suggesting that these genes are likely specific
modifiers of SMN loss of function defects.
Combined the results described here define eleven conserved
genes that modify invertebrate SMN ortholog function in at least
one assay in both C. elegans and Drosophila (summarized in Table 4).
A subset of these cross-species modifier genes interact, directly or
indirectly, with previously described neurological or neuromuscular
disease proteins suggesting common neurodegenerative pathways
may be at work (i.e. ATF6 with VAPB/ALS8 or GPRK2 and
SMN1 with FMRP) [75–77]. To determine if specific cellular
mechanisms could be implicated in SMN loss of function pathology,
the published literature and public databases were examined for
physical and/or functional interactions between cross-species SMN
modifier genes, SMN and neuromuscular disease genes. A protein/
genetic interaction map was assembled and is presented in Figure 7
with references. We note that genes implicated in endocytosis and
mRNA translational regulation unexpectedly predominate in this
interaction map. These two cellular pathways may be pertinent to
SMN loss of function pathology.
Discussion
Enormous effort over the last few decades has resulted in the
successful identification of numerous neurodegenerative disease
genes and the proteins they encode. However, in many cases there
remains considerable controversy as to why perturbation of these
genes results in neurodegeneration [78–81]. SMN plays a well-
Figure 6. Loss of Drosophila Cbp20 or FMRF enhances DmSmn loss of function neuromuscular defects. For two C. elegans modifier
genes, loss of function alleles were available for orthologous Drosophila genes: Cbp20 and FMRF [68–70]. Loss of either Drosophila gene enhanced
the NMJ defects of DmSmn animals. The number of synaptic boutons in the A2 segment of muscles 6 and 7 was counted in third instar larvae
(visualized using Discs large and synaptotagmin immunoreactivity, shown in red and green, respectively). Homozygous loss of DmSmn in
DmSmn
f1109/DmSmn
73Ao animals dramatically decreases bouton number but loss of one copy of DmSmn, Cbp20 or FMRF had little effect. Loss of one
copy of either Cbp20 or FMRF in animals heterozygous for either DmSmn allele significantly decreased bouton numbers. This nonallelic
noncomplementation suggests a strong genetic interaction between these two conserved modifier genes and DmSmn. Scale bar indicates 10
microns in representative images; S.E.M. is shown in graph; all transheterozygous combinations are significantly different from the corresponding
single heterozygous controls with p#0.05 by ANOVA as indicated with asterisk.
doi:10.1371/journal.pgen.1001172.g006
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assembly [8–10], yet SMA specifically affects neuromuscular
function, motorneuron survival, and leads to muscle atrophy.
Given this neuromuscular specificity, it seems likely that loss of
SMN function impacts cellular pathways outside of the Gemin
complex. In addition, given the complexity of cellular signaling
pathways, genetic pathways that are not directly involved in SMN
activity may impact SMN loss of function pathology. To identify
SMN modifier pathways, we have used a genetic approach.
Unbiased genetic screens are powerful tools as they utilize
functional criteria for the identification of genes critical for cellular
function. In the case of SMN loss of function, genetic screens can
reveal conserved genes and pathways that are important for
neuromuscular dysfunction and pathology independent of initial
assumptions about the roles of SMN in neurons and muscles. The
identification of hitherto unsuspected molecular pathways that
modulate SMN neuropathology, directly or indirectly, is expected
to widen the range of targets for SMA therapy development.
Conserved genes that modify SMN loss of function defects in
disparate species likely represent pathways that are important for
SMN loss of function defects or pathology. C. elegans and Drosophila
models have been used here to identify SMN loss of function
modifier genes that ‘cross species’. It is difficult to estimate how
many modifiers of SMN loss of function were missed in the
genome-wide C. elegans RNAi screen. ‘Growth’ encompasses a
variety of factors; slow progression through the larvae stages,
reduced growth in the adult stage, longevity, body size, different
culture format (liquid versus plates), or a combination of these.
Additionally, identification of genetic modifiers for a null allele can
be more challenging as compared to identification of genetic
modifiers for partial loss of function alleles [82]. No genetic screen
can identify all modifier genes pertinent to a pathway and
important players can be missed (e.g. miRNAs). Despite this, there
is excellent concordance of modifier gene action in C. elegans and
Drosophila. In most cases, genes that enhanced SMN loss of
function defects in Drosophila also enhanced SMN loss of function
defects in C. elegans and vice versa. This concordance suggests that
the genetic relationships between SMN and these modifier genes
are conserved across species. Orthologous genes are likely also
important in SMN loss of function pathology in vertebrate species,
as suggested by other invertebrate modifier screens that have
identified conserved human disease-related genes and/or func-
tional pathways [83–88].
Thus far, there are only two published human SMA modifier
genes: Plastin 3 (PLS3) and SMN2. The role of SMN2 is clear as it
provides a modicum of functional SMN protein. However, the
role of PLS3 in SMA is controversial and it is unclear how PLS3
levels might modulate severity in SMA patients [37,43]. We find
that invertebrate PLS3 orthologs act as modifiers in C. elegans and
Drosophila models. This cross-species interaction of PLS3 and SMN
both increases confidence in the invertebrate models and suggests
that plastin-associated pathways are important for SMN function
at a fundamental level in multiple contexts.
In the bioinformatic analysis presented in Figure 7, we
independently identified two cellular pathways that connect multiple
modifier genes with SMN: endocytosis and RNA processing/
translational control pathways. Regarding the former, it is of note
that the yeast ortholog of PLS3, Sac6p, is a key player in endocytosis
and Sac6p levels are critical when expanded polyglutamine
neurodegenerative disease proteins are expressed in this system
[42,89–91]. We suggest that 1) these two cellular mechanisms may
be of particular importance in SMA pathology and 2) that
unexpected and intimate connections exist between these two
pathways. A pair of recently published studies found that the
microRNAregulatory RISC complex and endocytosis are physically
and functionallycoupled innon-neuronalcells [92,93]. Interestingly,
the RISC complex also contains Gemin complex proteins; the
function of the Gemin and RISC complexes may be related, directly
or indirectly [20]. We speculate that in normal animals, physically
coupling the seemingly disparate pathways of endocytosis and local
translational regulation may help coordinate synaptic activity and
receptor signaling with protein translation during both synaptic
development and neuron maintenance [94]. Defects in endocytosis
have been suggested previously to play a pivotal role in
neurodegenerative diseases in numerous scenarios. In such diseases,
including SMA, perturbation of endocytosis may result in RNA
translational control defects, or vice versa [92,93]. A recent study has
demonstrated impairedsynaptic vesicle releaseat theNMJs insevere
SMA mice consistent with defects in synaptic vesicle endocytosis/
recycling and/or defects in active zone organization [94]. Further
Table 3. RNAi knockdown of candidate genes alters Cesmn-1(lf) neuromuscular defects in the pharyngeal pumping assay.
Cesmn-1(lf) +/Cesmn-1(lf) Cesmn-1(lf) Cesmn-1(lf)
% change vs. control RNAi empty(RNAi) candidate(RNAi)
Ce gene Dm gene Pumps/min
Cesmn-1 Smn 56619* 101625 3 692 7 66
plst-1 Fim 86621* 106615 3 694 3 68
daf-4 Wit 71627* 93623 8 672 6 66
kcnl-2 SK 147650* 90614 2 674 8 68
nhr-25 Usp 155645* 91654 8 686 7 611
C. elegans orthologs of DmSmn modifier genes whose RNAi knockdown altered Cesmn-1(lf) pharyngeal pumping defects are listed in column 1 and column 2,
respectively. The percent (%) change in pumping rates on empty vector RNAi versus candidate gene RNAi was determined independently in four separate experiments
and is reported with S.E.M. for both Cesmn-1(lf) homozygous mutant and +/Cesmn-1(lf) heterozygous control animals (columns 3 and 4). As pumping rates for each
genotype/treatment varied day-to-day (due to food thickness, etc.), % change versus empty vector RNAi controls is reported and was used to determine significance.
The overall pharyngeal pumping rates in columns 5 and 6 were calculated by pooling all Cesmn-1(lf) animals reared with the RNAi bacteria indicated (n.40 animals).
Animals were allowed to hatch on bacterial cultures carrying empty RNAi vector (empty) or RNAi constructs targeting C. elegans genes; pumping rates were determined
after 3 days at the early adult or late L4 larval stage as illustrated in Figure 2. Significance (indicated with an asterisk) was determined by a two-sample t-test/Mann-
Whitney U test according to sample-specific parameters (p#0.05). Two additional genes that modified growth CG33172/cash-1 and CG18375/ape-1 (Table S2), reached
significance here in pair-wise comparisons with controls. However, their knockdown enhanced Cesmn-1(lf) pumping defects in some trials and suppressed in other trials
resulting in no significant change in overall pumping rates. See Table S2 for results for all genes tested and Materials and Methods for details.
doi:10.1371/journal.pgen.1001172.t003
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tosis with translational controlpathwaysand to exploretherelevance
of these pathways in neurodegenerative disease.
Materials and Methods
Genetic analysis
Cesmn-1(lf) homozygous strains cannot be maintained due to
infertility; hT2(lethal)[myo-2p::GFP]/Cesmn-1(lf) (hT2[bli-4(e937) let-
?(q782)qIs48] (I;III)) animals are fertile and were maintained using
standard techniques [95]. The lack of homologous pairing for the
rearranged chromosomes LGI and LGIII in hT2 animals likely
results in increased maternal/zygotic expression of Cesmn-1 and
other balanced genes [96]. As expected, we found that the progeny
of hT2 animals were relatively resistant to Cesmn-1(RNAi)
compared to wild type control strains in our assays (data not
shown). Consequently, to keep the genetic background invariant,
all animals were tested herein were the progeny of hT2(lethal)[myo-
2p::GFP] parents. The use of RNAi sensitive C. elegans mutant
strains was avoided as their behavior is not normal in many assays
(Hart, unpublished observations) and because SMN complex/Sm
proteins have been implicated in miRNA pathways [20,97,98].
We note that RNAi knockdown is not always effective. To control
for genetic background effects, animals tested in these studies were
either heterozygous for hT2 balancer chromosome or progeny of
hT2 parents unless otherwise noted.
plst-1(tm4255) animals were obtained from the Japanese
National Bioresource Project and were backcrossed four times
before further study. The tm4255 allele is a 368 base pair deletion
that removes one of the calponin-like, actin-binding homology
(CH) domains; plst-1(tm4255) is likely a partial loss of function
allele. To test the genetic interaction of plst-1 with Cesmn-1, the
backcrossed plst-1(tm4255) allele was used to create a double
mutant with Cesmn-1(lf). The flp-4(yn35) deletion allele was isolated
by PCR-based screening of EMS-mutagenized animals. The yn35
allele is a 928 base pair deletion that removes exon 3 of flp-4 gene
along with 59 sequences (flanking sequences, ttctgaaaaacttttaataa
and agctcgccgagccgagtctt) [66]. The grk-2(rt97) loss of function
allele was previously characterized [60].
Drosophila stocks were maintained on standard cornmeal/yeast/
molasses/agar medium at 25uC. The mutations of Smn
73Ao and
Smn
f01109 have been described previously [25]. Cbp20
e02787 is a
Piggy-Bac insertion mutation from the Exelixis collection. The
insertion location is 59 upstream and adjacent to the start codon of
the Cbp20 transcript. Fmrf
KG1300 and Fim alleles are loss of
function alleles (Flybase). The line d03334 may have an unlinked
lethal mutation on another chromosome. Fim
d02114 and
SmnRNAi; Fim
d02114 have Tubulin:Gal4 in the background; this
Gal4 transgene does not alter Smn defects (data not shown).
Bioinformatics
C. elegans orthologs of Drosophila and human genes were
identified by BLAST searching at NCBI. When a clear ortholog
was not identified by reciprocal BLAST analysis, the most similar
C. elegans genes were generally tested. plst-1 corresponds to exons of
predicted adjacent genes Y104H12BR.1 and Y104H12BL.1 based
on similarity searching. T02G5.3 corresponds to exons of T02G5.3,
T02G5.2, and T02G5.1 based on high-throughput cDNA
sequencing and gene prediction programs [99]. New gene
predictions have been reported to Wormbase. To assemble the
interaction map in Figure 7, literature pertaining to each modifier
gene was examined at NCBI, AceView, C. elegans and yeast on-line
databases (Wormbase and SGD) to identify functional or direct
interactions between modifier genes and neurodegenerative
disease genes.
Construction of RNAi feeding clones for B0432.13, dhs-22
and ugt-49
The L4440 vector [47] was used to clone PCR products
corresponding to B0432.13, dhs-22 and ugt-49 genes. Plasmids were
transformed into the bacterial strain HT115(DE3) [47,49]. Primers
used for cloning were: B0432.13 forward 59-acaagctctcgacatcgctg-
39, reverse 59- ttaatcgccgcatcctcttg -39; dhs-22 forward 59-tatgctgtg-
cagaagcgaag-39, reverse 59-ctgcttgattcctggtgtattc-39; ugt-49 forward
59-acgtggatgtagctgaatgg-39, reverse 59- acgtgaagaacagcaacgaac-39.
C. elegans growth studies
For analysis of modifier genes, animals were reared for two
generations/5 days on plates spread with bacterial RNAi strains
from the Ahringer or Vidal RNAi libraries [53]. RNAi clones
Table 4. Summary: Invertebrate modifiers of SMN loss of
function.
Ce
gene
Dm
gene
Hs
gene
Change/
Affect Ce
Change/
Affect
Dm
plst-1 Fim Plastin 3 (PLS3) RNAi/Cmpx Gr,
Enh Pump
Lof/Enh
daf-4 Wit TGFb receptor (BMPRII) RNAi/Enh Pump Lof/Enh
kcnl-2 SK SK channel (KCNN3) RNAi/Enh Gr,
Sup Pump?
Lof/Enh
nhr-25 Usp NHR LRH-1 (NR5A2) RNAi/Sup Pump OE/Enh
uso-1 p115 Vesicle docking (USO1) RNAi/Enh Gr OE/Sup
nhr-85 Eip75B NHR RevErb (NR1D2) RNAi/Enh Gr Lof/Enh
atf-6 Atf6 Atf6 trans. factor (ATF6) RNAi/Enh Gr ?/Sup
egl-15 Btl FGF receptor (FGFR3) RNAi/Enh Gr Lof/Enh
ape-1 CG18375 p53 inhibition (PPP1R13) RNAi/Enh Gr ?/Enh
nekl-3 Nek2 NIMA family kinase (NEK7) RNAi/Enh Gr OE/Sup
atn-1 Actinin a-actinin (ACTN) RNAi/Sup Gr OE/Enh
cash-1 CG33172 Striatin (STRN) RNAi/Cmpx Gr Lof/Enh
dlc-1 cut up Dynein light chain (DYNLL2) RNAi/Cmpx Gr Lof/Sup
ncbp-2 CBC20 Cap binding (CBP20) RNAi/Enh Gr &
Pump
Lof/Enh
grk-2 Gprk GRK kinase (ADRBK1) RNAi/Enh Gr &
Pump
n.d.
flp-4 FMRF Neuropeptide (NPFF) RNAi/Enh Gr Lof/Enh
T02G5.3 none none RNAi/Enh Gr,
Sup Pump
n.d.
The summary table is divided into three sections corresponding to potential
Cesmn-1(lf) modifier genes originally identified in humans, Drosophila,o rC.
elegans (1 in Hs,4 0i nDm,a n d4i nCe, respectively). Species and gene names
are listed in the first three columns. The change in gene expression due to
Drosophila GAL4-driven transposon insertion lines or C. elegans RNAi
knockdown is listed in columns 4 and 5; effect on Drosophila gene function is
predicted based solely on transposon insertion sites in some cases. (RNAi: RNAi
knockdown; Lof: loss of function; decreased function or antisense; OE: over-
expression; ?: unclear; Enh: enhanced SMN loss of function defects; Sup:
suppressed SMN loss of function defects, Cmpx: complex genetic interaction;
not determined, n.d.). Column 4 includes the C. elegans assay revealing modifier
activity (Gr: growth; Pump: pharyngeal pumping.) RNAi knockdown was
sufficient to modify pumping rates for T02G5.3 and ncbp-2; mutant alleles of
grk-2 exacerbated Cesmn-1(lf) pumping defects. flp-4 loss decreased Cesmn-1(lf)
pumping rates in 4 out of 5 trials, but did not reach significance overall.
Discordance between Drosophila and C. elegans results is indicated with ?.
doi:10.1371/journal.pgen.1001172.t004
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confirm accuracy. The hlh-4(RNAi) clone in the feeding library was
incorrect. A Cesmn-1(ok355);hlh-4(tm604) double mutant strain was
generated. hlh-4(tm604) did not affect the pharyngeal pumping
rates of Cesmn-(lf) (data not shown) and hlh-4 was excluded from
further analysis. Length and GFP fluorescence was determined
using the COPAS Biosorter (Union Biometrica, Holliston, MA)
and the percentage of large animals was determined for each
genotype [51]. Three to six independent determinations were
undertaken for each genotype/RNAi culture. Significant changes
from empty(RNAi) were calculated for each RNAi/genotype using
the two-tailed Mann-Whitney U test.
C. elegans pharyngeal pumping
The average pharyngeal pumping rates of animals were
determined after 3 days (at 25, 25 and 20uC) post-hatching on
Figure 7. Interaction map of SMN modifier genes. A) Numerous published physical and/or functional interactions were found in the literature
that connect many invertebrate SMN modifier genes. The names of vertebrate genes are used in the figure, but interactions are drawn from literature
in any animal species. Each type of interaction is represented by different colors of connecting lines and references are provided in the table in part B.
Not all interactions are indicated including interactions of FGF, TGF-beta and neuropeptide signaling pathways with endocytosis/cytoskeletal
pathways, dynein interactions with APP [101] and possible connection between VAPB, the ALS8 locus, and SK channels through riluzole [102–106].
The interaction analysis here is not exhaustive and additional interactions may exist. B) The type of interaction is indicated in the table [107–155]:P
pull-down, Y yeast 2-hybrid, F functional/genetic, D direct physical interaction. Genes shaded in blue are cross-species invertebrate modifiers; genes
shaded in yellow are mammalian genes whose perturbation can cause neurodegeneration; genes outlined in grey are SMA modifiers in drug studies
or in patients. Genes pertinent to endocytosis include CIN85, EndoA, Alix, PLS3, CAV1, GPRK, Ataxin2, Profilin, EPS15, Phocein, Dynamin, and Striatin;
genes pertinent to RNA processing include PABP, CBC20, DcpS, SMN, and FMRP. Combined, our results and published studies support a model in
which endocytosis and RNA translational control pathways are physically and functionally coupled [92,93]. In normal animals, coupling of these
seemingly disparate pathways may help coordinate synaptic activity and protein synthesis in the neuromuscular system.
doi:10.1371/journal.pgen.1001172.g007
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feeding strains. Animals were videotaped while feeding for
10 seconds with an AxioCam ICc1 camera on a Zeiss Stemi
SV11 at 20 to 666 magnification. Movies were slowed before
counting pumping rates. Pharyngeal grinder movements in any
axis were scored as a pumping event. Average pumping rates (6
standard error of the mean, S.E.M) for each genotype/treatment
were calculated independently in two to four separate experi-
ments. The percent change in pumping rate on empty vector versus
candidate gene RNAi was determined for each trial for both
Cesmn-1(lf) homozygous and +/Cesmn-1(lf) heterozygous animals
and used to calculate the mean, S.E.M, and significance.
C. elegans genome-wide RNAi screen
hT2(bli-4(e937) let-?(q782) qIs48[myo-2p::GFP]) (I;III) animals
were reared in liquid cultures in a 96-well plate format on RNAi
feeding strains [53]. At least two independent cultures corre-
sponding to each C. elegans RNAi feeding clone were established.
Concentrated dsRNA expressing bacteria was added to cultures as
necessary to prevent starvation. Cultures were maintained for 8
days at 25uC to generate sufficient animals for analysis. Length
and fluorescence were determined using the COPAS BioSorter
(Union Biometrica, Holliston, MA). Data was exported to Excel
(Microsoft Corp.) for analysis. Thirty-one clones were identified
that modified the average length of Cesmn-1(lf) animals relative to
+/Cesmn-1(lf) siblings in both trials. Four of these genes altered
Cesmn-1(lf) size relative to +/Cesmn-1(lf) siblings in at least 40% of
subsequent trials and these were selected as candidate modifier
genes for neuromuscular analysis as described in the text.
Drosophila pupal lethality
Three males and three virgin females were placed on fresh food
at 25uC on day 1. Eggs were collected for next 2 days (Set 1), and
the parents transferred to fresh food. Eggs were collected for
another 2 days (Set 2), and the parents discarded. The F1 animals
were scored after 15 days,- on the 16
th day for the first set, and the
19th day for the second set, from day 1. White pupae were scored
as early stage death and black pupae were scored as late stage
death. Control crosses of tubGAL4:FL26B(Smn RNAi) out-
crossed to the wild type strain were used as a control for every
experimental set. Significance was determined by Chi-square
analysis.
Drosophila NMJ analysis
Primary antibodies were used at the following dilutions:
monoclonal anti-DLG (1:500) (Developmental Studies Hybridoma
Bank), polyclonal anti-Synaptotagmin (1:1000) (a gift from Hugo
Bellen). FITC- (1:40) and Cy5- (1:40) conjugated anti-rabbit and
anti-mouse secondary antibodies were purchased from Jackson
Immunoresearch Laboratories. Anti-Disc large used at 1:100
(Hybridoma) and anti-HRP used at 1:1000 (Cappell). 3
rd instar
larvae were dissected and fixed for 5 minutes in Bouin’s fixative.
Stained specimens were mounted in FluoroGuard Antifade
Reagent (Bio-Rad), and images were obtained with a Zeiss
LSM510 confocal microscope. Bouton numbers were counted
based on the Discs large and Synaptotagmin staining in the A2
segment between muscles 6 and 7 or muscle 4 as indicated. The
ratio of muscle area for the various genotypes was normalized to
wild type. At least 10–12 animals of each genotype were dissected
for the bouton analysis. The ANOVA multiple comparison test
was used for statistical analysis.
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